At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 276 enrolled
Drug / intervention
ABT-494 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy
In Brief
A Phase 2 clinical trial evaluating ABT-494 and Placebo for Rheumatoid Arthritis. Completed, enrolled 276 participants.
Detailed Summary
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to anti-TNF biologic therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionJul 2015
TodayJul 2026
First PostedOct 11, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.7 years ago
Interventions
ABT-494drug
ABT-494 capsule administered orally twice daily (BID).
Placebodrug
Placebo for ABT-494 capsule administered orally twice daily (BID).